Literature DB >> 10980279

Levosimendan improves diastolic and systolic function in failing human myocardium.

P M Janssen1, N Datz, O Zeitz, G Hasenfuss.   

Abstract

Ca(2+)-sensitizers increase myocardial contractility, but may worsen diastolic dysfunction. Levosimendan, through its unique troponin-C interaction, may preserve diastolic function. We investigated the effects of levosimendan (10(-7)-10(-5) M) on diastolic and systolic function in multicellular cardiac muscle preparations from end-stage failing human hearts (1 and 2.5 Hz, 37 degrees C, 1.25 mM [Ca(2+)], pH 7.4). Levosimendan improved systolic function: at 1 Hz, developed force (F(dev)) increased from 13.84+/-3.27 to 16.40+/-3.57 (10(-7) M, P<0.05), while diastolic force (F(dia)) decreased from 5.32+/-0.67 to 4.94+/-0.61 mN/mm(2) (P<0.05). Under control conditions, the increase in stimulation frequency from 1 to 2.5 Hz resulted in a decrease in F(dev) of -0.51+/-1.80 mN/mm(2) (negative force-frequency relationship). Levosimendan improved this relationship: at 10(-7) M, this change became positive (+1.81+/-2.06 mN/mm(2), P<0.05). Diastolic function was markedly improved in the presence of levosimendan; the increase in F(dia) of 1.56+/-0.42 mN/mm(2) (control) was attenuated to 0.70+/-0.19 mN/mm(2) (P<0.05). To allow for a more detailed analysis, preparations were sometimes divided into two groups, based on their force-frequency behavior. Twitch timing parameters were accelerated by levosimendan in preparations with a negative force-frequency relationship. Levosimendan improves both systolic and diastolic function in failing human myocardium. Effects are even more pronounced at higher heart rates and under prevailing diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980279     DOI: 10.1016/s0014-2999(00)00609-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

2.  [Acute perioperative right heart insufficiency : Diagnostics and treatment].

Authors:  B Schäfer; C-A Greim
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

Review 3.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

Authors:  S Rehberg; C Ertmer; H Van Aken; M Lange; K Bröking; A Morelli; M Westphal
Journal:  Anaesthesist       Date:  2007-01       Impact factor: 1.041

5.  Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium.

Authors:  Regis R Lamberts; Nazha Hamdani; Tenoedj W Soekhoe; Nicky M Boontje; Ruud Zaremba; Lori A Walker; Pieter P de Tombe; Jolanda van der Velden; Ger J M Stienen
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

6.  Calcium sensitivity, force frequency relationship and cardiac troponin I: critical role of PKA and PKC phosphorylation sites.

Authors:  Genaro A Ramirez-Correa; Sonia Cortassa; Brian Stanley; Wei Dong Gao; Anne M Murphy
Journal:  J Mol Cell Cardiol       Date:  2010-01-18       Impact factor: 5.000

Review 7.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Sex-specific modification of progesterone receptor expression by 17β-oestradiol in human cardiac tissues.

Authors:  Georgios Kararigas; Eva Becher; Shokoufeh Mahmoodzadeh; Christoph Knosalla; Roland Hetzer; Vera Regitz-Zagrosek
Journal:  Biol Sex Differ       Date:  2010-11-04       Impact factor: 5.027

Review 10.  A review of levosimendan in the treatment of heart failure.

Authors:  Hulya Akhan Kasikcioglu; Nese Cam
Journal:  Vasc Health Risk Manag       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.